Biopeople

Microscopy Leader

Microscopy Leader

22.08.2014 - Alex Blanchard has taken over the lead for the Microscopy Group of Reading Scientific Services Ltd (RSSL), a analytical service provider to the global food, drink, pharmaceutical and healthcare sectors.

Blanchard was previously Group Analytical and Microbiology Manager at Rentokil Initial. Prior to that he led Procter & Gamble's European Microbiology Department, where he oversaw microbiology risk management for a wide range of products. He was also Global Microbiology Leader for Visualisation and Demos using the latest microscopy capabilities.

As RSSL's Senior Group Leader of Microscopy, Blanchard will head the section using microscopy techniques for projects in new product development.

http://www.european-biotechnology-news.com/people/bio-people/2014/alex-blanchard.html

21.08.2014 Swedish pharmaceutical company Medivir has a new president and CEO: board member Niklas Prager is succeeding Maris Hartmanis effective September 1st.

© Medivir

Prager has long experience of senior executive positions in trade and industry - both as CEO and as board member. He is currently chairman of the board of Qbtech AB and a member of the board of Egain Group AB. Before that, he was chairman of the boards of Biophausia AB, Envirotainer AB and Michael Berglund Search Group AB. He has also served as the CEO of Pfizer AB, Envirotainer AB and Qbtech AB. Stockholm-based Medivir expects a strong contribution to the company's strategic business development and commercialisation of its product portfolio. Prager commented: "An update of Medivir’s strategic plan is the number one priority, and work on this is already well under way."

18.08.2014 Adrian Percy has taken over the position of Global Head of Research and Development at Bayer Cropscience and is also the newest member of the Excecutive Committee.

© Bayer Cropscience

Most recently, Percy was responsible for for regulatory affairs activities at Bayer Cropscience as Senior Vice President of Global Regulatory Affairs. Before that, he held numerous positions in the Research and Development departments of the German company and its legacy companies in France, Germany and the USA. He grew up and studied in the United Kingdom earning a Bachelor’s degree in Pharmacology at the University of Liverpool, a Master’s degree in Toxicology and then a doctorate in Biochemistry at the University of Birmingham. Percy succeeds David Nicholson, who has left the company.

14.08.2014 Matthew Pauls is taking over the leadership for Swedish biopharmaceutical company Cortendo AB. With his extensive pharma background and experience in commercial operations, Pauls aims to orient Cortendo toward product commercialisation.

Cortendo AB

Once Pauls has taken over the new role of president and CEO, erstwhile CEO Joseph Reiser will assume the position of chairman of the board. Current chairman Eigil Stray Spetalen will step down to assume a regular board position.

Before joining Cortendo, Pauls was Chief Commercial Officer of US biopharmaceutical company Insmed, Inc, and before that, he worked at Shire Pharmaceuticals, most recently as Senior Vice President, Head of Global Commercial Operations. Pauls also held positions at Bristol-Myers Squibb in Brand Management and Payor Marketing and at Johnson & Johnson in various US and global commercial roles. Mr. Pauls holds BS and MBA degrees from Central Michigan University and a JD from Michigan State University College of Law.

07.08.2014 John P. Donoghue is taking over the management of the Geneva Wyss Center for Bio-and Neuro-engineering at Campus Biotech.

campus biotech

The internationally recognised neuroscientist was also appointed adjunct professor at the École Polytechnique Fédérale de Lausanne (EPFL) and visiting professor at the University of Geneva. Donoghue is the founder of Brown University’s Institute for Brain Science in Rhode Island, USA, and works as a professor of neuroscience and engineering at Brown University. He also holds the Henry Merritt Wriston chair. He will take a one year sabbatical from Brown in 2015 during which he will be devoted to his position as Head of the Wyss Center.

Donoghue is among the founding fathers of neuroprosthetics - the merger between neuroscience and cybernetics. He is best known for having developed innovative brain-computer interfaces for people with paralysis.

11.08.2014 Sir Alec Jeffreys has been awarded the Royal Society’s Copley Medal. The British geneticist received the medal for his pioneering work on variation and mutation in the human genome.

Jane Gitschier, PLoS Genetics

Jeffreys is well known for his 1984 discovery of a method to show the variation between individuals’ DNA, a technique which became known as genetic fingerprinting.  He made the discovery in his lab at the University of Leicester after looking at an X-ray image of the DNA of the different members of his lab technician’s family. Genetic fingerprinting has since been used to resolve issues of identity and kinship, becoming a formative method used in modern forensic science. Jeffreys continued working with this method, further refining it towards DNA profiling. “Sir Alec’s work has transformed our understanding of human genetics“, said Sir Paul Nurse, President of the Royal Society.

The Royal Society awards the Copley medal since 1731, making it the scientific prize believed to be the oldest in the world. It is awarded for outstanding achievements in scientific research. Before Jeffreys, scientists such as Charles Darwin, Michael Faraday, Albert Einstein and Stephen Hawking have been awarded.

04.08.2014 Former Merck & Co. president for Europe and Canada Bruno Strigini has been appointed president of Novartis Oncology.

Novartis Oncology

Right off the bat, Strigini’s career started off internationally, with an MBA from Swiss IMD, a doctorate degree in pharmacy from the French University of Montpellier, and a master's degree in microbiology from UK’s Heriot-Watt University. Since then, he has worked in pharmaceuticals, animal health, OTC and vaccines for 25 years. Strigini has held increasingly senior executive positions in a number of companies, such as Schering-Plough, UCB-Celltech and SmithKline Beecham. Previous roles have included President of International Operations, President of Japan and Asia-Pacific, and Senior Vice-President and Head of Global Marketing & Business Development, as well as Managing Director positions in New Zealand, the UK and Spain.

His expertise stretches across diverse geographies, including both mature and emerging markets. He is a member of the Executive Committee for the European Federation of Pharmaceutical Industries & Associations (EFPIA), as well as a member of the Académie Nationale de Pharmacie in France.

29.07.2014 The UK government has named George Freeman, MP, as minister for life sciences. The position has been newly created and is aimed to bridge the departments of health and business.

George Freeman

Freeman has extensive background as a biotech venture capitalist. Before being elected to Parliament in 2010, he was Founder and Chairman of 4D Biomedical Ltd, a specialist translational medicine consultancy. Before that, he was CEO of Cambridge-based start-up Amedis Pharmaceuticals and Director of Early Stage Ventures at Merlin Biosciences.

Freeman served as Government Life Science Advisor from 2011 to 2013 to the Minister of State for Universities and Science. In this capacity, he supported the coordination of the Prime Minister's Life Science Strategy. He is involved in the UK Government department UK Trade & Investment (UKTI) to promote the UK Life Science sector including representing the UK Government on trade missions to the USA and Sweden.

25.07.2014 With the appointment of Ann-Tove Kongsnes and Hilde Furberg to its board of directors, Swedish specialty pharma company Pharmalink AB has gained experts from both business development and pharmaceuticals.

Pharmalink AB

Ann-Tove Kongsnes is an Investment Director at Pharmalink investor company Investinor, which is Norway’s largest investor in venture and expansion capital. She was previously an investment manager at ProVenture Managment AS and worked as a Business Development Manager at Leiv Eiriksson Nyskaping AS, among others. In addition to Pharmalink, Kongsnes is a board member of Investinor’s portfolio companies Ayanda AS, Nordic Seafarms AS, Polight AS, and Soundrop AS. She is also deputy board member at Bergenbio AS and head of International Affairs at Investinor.

Hilde Furberg has 30 years of experience in the pharmaceutical industry. She is currently Senior Vice President Rare Disease EMEA at Sanofi’s Genzyme, which she joined in 2002. Prior to Genzyme, Furberg spent 15 years at health care company Baxter in various business roles of increasing seniority, before which she was involved in the start-up of Pharmalink. She used to sit on the board of companies such as Algeta ASA, Clavis Pharma ASA, Pronova Biopharma ASA and Probi AB.

At the shareholders’ meeting that saw the two new board members, Elisabeth Lindner stepped down from the board while Olav Hellebø was also elected new member.

12.07.2014 Will Lewis has joined Uniqure’s supervisory board in June 2014. The human gene therapy specialist company expects to profit from Lewis’ expertise in both scientific and financial aspects of management as well as experience in orphan diseases.

Uniqure

Will Lewis has more than 20 years of executive experience in the pharmaceutical and finance industries both in the US and internationally. He served as president and CEO and as a member of the Board of Directors of Insmed, a US biopharma company specialised in inhalation therapies for orphan lung diseases. He co-founded Aegerion Pharmaceuticals, where he also filled the role of president and chief financiel officer. Prior to Aegerion, Lewis spent 10 years working in the U.S. and Europe in investment banking for JP Morgan, Robertson Stephens and Wells Fargo.

Lewis also serves as a member of the board of directors of Oberlin College and is a member of the Visiting Committees of the Weatherhead School of Management of Case Western Reserve University and The Hawken School. Jörn Aldag, CEO of uniQure, commented “[Lewis’] exceptional experience in the field of orphan diseases as well as his broad knowledge of the US and European financial markets will be of high value to the company.”

08.07.2014 Swiss start-up Spinomix has added long-time investor Dr. K. Peter Hirth to its Board of Directors.

K. Peter Hirth

Hirth received his Ph.D. in molecular genetics from Heidelberg and worked as a research scientist with the German Max Planck Institute before joining Boehringer Mannheim as Vice President of Research. As president, he helped build US drug discovery company Sugen from its inception. From 2001 onwards, Hirth served as co-founder and CEO of Plexxikon, where he built a drug discovery platform to bring several new chemical entities into the clinic in a variety of indications. Hirth currently serves as a Board member of KineMed, Kolltan and Alios Biopharma. Lausanne-based Spinomix hopes that the appointment of Hirth will help develop the technology platform company towards commercial maturity.

1/20Nächste Seite

Events

All Events

Stock list

All quotes

TOP

  • 4SC1.23 EUR0.00%
  • ACTELION108.80 CHF0.00%
  • ADDEX4.00 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC1.23 EUR0.00%
  • ACTELION108.80 CHF0.00%

TOP

  • SANTHERA82.95 CHF20.4%
  • LONZA101.10 CHF6.1%
  • MAGFORCE6.50 EUR5.7%

FLOP

  • WILEX2.36 EUR-25.1%
  • MOLOGEN7.10 EUR-24.5%
  • VITA 343.96 EUR-18.4%

TOP

  • SANTHERA82.95 CHF3758.1%
  • CO.DON2.50 EUR228.9%
  • PAION2.48 EUR195.2%

FLOP

  • CYTOS0.26 CHF-93.6%
  • MEDIGENE4.65 EUR-68.1%
  • MERCK KGAA64.40 EUR-45.7%

No liability assumed, Date: 22.08.2014


Current issue

All issues

Product of the week

Products